Login to Your Account

Other News To Note

Friday, May 13, 2011
Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said the European Medicines Agency acknowledged the company's dossier for Scenesse (afamelanotide) in erythropoietic protoporphyria (EPP) met all filing requirements. EPP is an orphan disease causing absolute intolerance to light; Scenesse activates melanin to reduce the cytotoxic reactions in those patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription